An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Cardiovascular Systems, Inc. to Participate at SVB Leerink 2022 Global Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Cardiovascular Systems, Inc. (CSII), a medical device company based in St. Paul, Minnesota, announced its participation in the SVB Leerink 2022 Global Healthcare Conference on February 18, 2022, at 12:00 p.m. ET. The company specializes in innovative interventional treatment systems for patients with peripheral and coronary artery disease. A webcast of the presentation will be available here.
Positive
None.
Negative
None.
ST. PAUL, Minn.--(BUSINESS WIRE)--
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host investor meetings at the SVB Leerink 2022 Global Healthcare Conference on February 18th. A webcast of the presentation will be made available here.
SVB Leerink 2022 Global Healthcare Conference
Friday, February 18, 2022 12:00 p.m. ET
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s orbital atherectomy system treats calcified and fibrotic plaque in arterial vessels throughout the leg and heart and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. For additional information, please visit www.csi360.com and connect on Twitter @csi360.
